UGCG (Glucosylceramide Synthase) Drug Discovery Landscape & Assay Solutions
- By admin
- 20 Aug 2026
- Comments
Substrate Reduction Therapy & Cancer Multidrug Resistance Target: High-purity enzymatic reagents for Gaucher disease, Fabry disease, and oncology drug development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UGCG pathway research. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UGCG Full-Length Recombinant Protein HEK293 expressed, Detergent-soluble, >90% purity. Sequence Verified. Theoretical MW confirmed. |
View UGCG Products |
| Gene Delivery | UGCG Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Endotoxin controlled. |
View UGCG Products |
| Benchmark Ab | Anti-UGCG Antibody Recombinant positive control for western blot/IHC. |
View UGCG Products |
| Validator | UGCG siRNA Set For knockdown verification and specificity controls. |
View UGCG Products |
| Related Target: GBA | GBA (Beta-Glucocerebrosidase) Lysosomal enzyme deficient in Gaucher disease; metabolic partner in glycolipid degradation. |
View GBA Products |
| Related Target: SPTLC1 | SPTLC1 (Serine Palmitoyltransferase) Rate-limiting enzyme upstream of ceramide synthesis; substrate reduction pathway target. |
View SPTLC1 Products |
| Related Target: ABCB1 | ABCB1 (MDR1) Multidrug resistance efflux pump; functional link to UGCG-mediated chemoresistance. |
View ABCB1 Products |
| Related Target: GLA | GLA (Alpha-galactosidase A) Target for Fabry disease; pathway synergy with UGCG in lysosomal storage disorders. |
View GLA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane Protein Solubility & Native Conformation | Detergent-soluble full-length protein expressed in HEK293; preserves transmembrane domains for functional assays |
| Enzymatic Activity Validation | Sequence-verified catalytic domain available; theoretical MW confirmed by mass spec analysis |
| Selectivity vs Lysosomal Hydrolases (GBA) | Strict sequence verification ensures no cross-reactivity with glucocerebrosidase; distinct epitope mapping |
| Pathway Cross-Talk Studies | Co-expression systems available with SPTLC1 and GBA for sphingolipid flux analysis |
| False Positives in Inhibitor Screening | Validated siRNA included for specificity checks; sequence-verified controls eliminate off-target artifacts |
Live UGCG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The UGCG inhibitor landscape is bifurcated between established rare disease therapeutics and emerging oncology applications. Following the FDA approval of eliglustat (Sanofi Genzyme) for Gaucher disease Type 1, the field is witnessing renewed interest in substrate reduction therapy (SRT) for neuronopathic variants and Parkinson's disease with GBA mutations. Major players are shifting focus from traditional enzyme replacement to oral small molecule SRTs, with next-generation candidates targeting brain-penetrant inhibitors for neurological phenotypes in lysosomal storage disorders and oncology drug resistance. Simultaneously, oncology programs are targeting UGCG-mediated multidrug resistance (MDR), where glucosylceramide accumulation correlates with chemotherapy failure in hematologic malignancies and solid tumors. The next wave of R&D is targeting blood-brain barrier penetrant inhibitors for CNS indications and combination therapies pairing UGCG inhibition with proteostasis regulators.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (SRT) | Sanofi, Amicus, Johnson & Johnson | Gaucher Disease Type 1, Fabry Disease, GBA-Parkinson's | Enzymatic Inhibition Assay (Need purified native-conformation UGCG) |
| Small Molecule (Cancer MDR) | Oncology biotechs | Hematologic Malignancies, Drug-resistant Solid Tumors | Cell-based Glucosylceramide Accumulation Assay (Need Lentivirus-stable lines) |
| Gene Therapy | Prevail Therapeutics | GBA-Parkinson's, Lysosomal Storage Disorders | Pathway Flux Analysis (Need UGCG+GBA co-expression systems) |
| Antisense Oligonucleotides | Ionis Pharma | Neuronopathic Gaucher Disease | Knockdown Validation (Need high-efficiency siRNA controls) |